(NEO) NeoGenomics - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 1.370m USD | Total Return: 41.1% in 12m
Avg Turnover: 12.4M
Qual. Beats: 0
Rev. Trend: 99.7%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -36.4 is critical
Tailwinds
Tailwind
NeoGenomics, Inc. (NEO) operates a specialized network of diagnostic laboratories in the United States and the United Kingdom, focusing exclusively on oncology-related testing. The company provides a broad suite of clinical services including cytogenetics, flow cytometry, and molecular testing to hospitals, pathologists, and pharmaceutical researchers. By integrating morphologic analysis with advanced genomic sequencing, the firm supports both individual patient diagnosis and drug development programs.
The specialized laboratory sector operates under a high-complexity regulatory framework, where business models often rely on a hub-and-spoke distribution to process samples from diverse clinical locations. As precision medicine increases the demand for targeted cancer therapies, diagnostic providers like NeoGenomics serve as critical intermediaries in identifying specific genetic biomarkers. Investors can further evaluate these industry tailwinds and valuation metrics at ValueRay.
Founded in 2001 and headquartered in Fort Myers, Florida, NeoGenomics maintains a dual-revenue stream by serving both the clinical market for patient care and the biopharmaceutical market for clinical trials. This model allows the company to leverage its testing infrastructure across the entire oncology lifecycle, from early-stage discovery to commercial diagnostics.
- Next-generation sequencing adoption accelerates high-margin clinical revenue growth
- Biopharmaceutical research spending fluctuations impact pharma services segment profitability
- Medicare reimbursement rate adjustments influence overall diagnostic testing margins
- Precision medicine demand drives volume across specialized oncology testing platforms
- Operational efficiency initiatives target reduction in cost per clinical test performed
| Net Income: -99.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 1.64 > 1.0 |
| NWC/Revenue: 38.75% < 20% (prev 43.76%; Δ -5.01% < -1%) |
| CFO/TA 0.02 > 3% & CFO 22.4m > Net Income -99.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (25.8m) vs 12m ago 1.41% < -2% |
| Gross Margin: 42.13% > 18% (prev 44.30%; Δ -2.17% > 0.5%) |
| Asset Turnover: 50.61% > 50% (prev 41.99%; Δ 8.62% > 0%) |
| Interest Coverage Ratio: -36.37 > 6 (EBIT TTM -99.4m / Interest Expense TTM 2.73m) |
| A: 0.21 (Total Current Assets 373.7m - Total Current Liabilities 84.6m) / Total Assets 1.35b |
| B: -0.33 (Retained Earnings -450.9m / Total Assets 1.35b) |
| C: -0.07 (EBIT TTM -99.4m / Avg Total Assets 1.47b) |
| D: 1.60 (Book Value of Equity 828.8m / Total Liabilities 517.8m) |
| Altman-Z'' = 1.54 = BB |
| DSRI: 1.00 (Receivables 167.4m/151.2m, Revenue 746.0m/672.4m) |
| GMI: 1.05 (GM 44.30% / 42.13%) |
| AQI: 1.12 (AQ_t 0.60 / AQ_t-1 0.54) |
| SGI: 1.11 (Revenue 746.0m / 672.4m) |
| TATA: -0.09 (NI -99.2m - CFO 22.4m) / TA 1.35b) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of June 03, 2026, the stock is trading at USD 10.12 with a total of 1,029,362 shares traded.
Over the past week, the price has changed by +9.17%,
over one month by +12.44%,
over three months by +6.53% and
over the past year by +41.14%.
NeoGenomics has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy NEO.
- StrongBuy: 6
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.1 | 48.8% |
P/E Forward = 222.2222
P/S = 1.8363
P/B = 1.6529
P/EG = 2.0871
Revenue TTM = 746.0m USD
EBIT TTM = -99.4m USD
EBITDA TTM = -32.9m USD
Long Term Debt = 342.2m USD (from longTermDebt, last quarter)
Short Term Debt = 4.83m USD (from shortTermDebt, last quarter)
Debt = 474.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 66.3m
Net Debt = 328.7m USD (calculated: Debt 474.8m - CCE 146.1m)
Enterprise Value = 1.70b USD (1.37b + Debt 474.8m - CCE 146.1m)
Interest Coverage Ratio = -36.37 (Ebit TTM -99.4m / Interest Expense TTM 2.73m)
EV/FCF = -333.8x (Enterprise Value 1.70b / FCF TTM -5.09m)
FCF Yield = -0.30% (FCF TTM -5.09m / Enterprise Value 1.70b)
FCF Margin = -0.68% (FCF TTM -5.09m / Revenue TTM 746.0m)
Net Margin = -13.30% (Net Income TTM -99.2m / Revenue TTM 746.0m)
Gross Margin = 42.13% ((Revenue TTM 746.0m - Cost of Revenue TTM 431.7m) / Revenue TTM)
Gross Margin QoQ = 43.32% (prev 39.81%)
Tobins Q-Ratio = 1.26 (Enterprise Value 1.70b / Total Assets 1.35b)
Interest Expense / Debt = 0.58% (Interest Expense 2.73m / Debt 474.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -78.5m (EBIT -99.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.42 (Total Current Assets 373.7m / Total Current Liabilities 84.6m)
Debt / Equity = 0.57 (Debt 474.8m / totalStockholderEquity, last quarter 828.8m)
Debt / EBITDA = -9.99 (negative EBITDA) (Net Debt 328.7m / EBITDA -32.9m)
Debt / FCF = -64.60 (negative FCF - burning cash) (Net Debt 328.7m / FCF TTM -5.09m)
Total Stockholder Equity = 839.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.73% (Net Income -99.2m / Total Assets 1.35b)
RoE = -11.82% (Net Income TTM -99.2m / Total Stockholder Equity 839.4m)
RoCE = -8.41% (EBIT -99.4m / Capital Employed (Equity 839.4m + L.T.Debt 342.2m))
RoIC = -6.39% (negative operating profit) (NOPAT -78.5m / Invested Capital 1.23b)
WACC = 6.99% (E(1.37b)/V(1.84b) * Re(9.25%) + D(474.8m)/V(1.84b) * Rd(0.58%) * (1-Tc(0.21)))
Discount Rate = 9.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 1.13%
[DCF] Fair Price = unknown (Cash Flow -5.09m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.02 | # QB: 0
Revenue Correlation: 99.74 | Revenue CAGR: 11.12% | SUE: 0.71 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.03 | Chg30d=N/A | Revisions=-20% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.05 | Chg30d=+2.44% | Revisions=+0% | Analysts=11
EPS current Year (2026-12-31): EPS=0.18 | Chg30d=+16.13% | Revisions=+0% | GrowthEPS=+50.0% | GrowthRev=+10.1%
EPS next Year (2027-12-31): EPS=0.36 | Chg30d=+12.88% | Revisions=+40% | GrowthEPS=+102.5% | GrowthRev=+10.0%
[Analyst] Revisions Ratio: +40%